<DOC>
	<DOCNO>NCT00706641</DOCNO>
	<brief_summary>This pilot study design determine feasibility safety treatment dasatinib administer orally daily 4 week duration prior radical cystectomy urothelial carcinoma bladder .</brief_summary>
	<brief_title>Neoadjuvant Dasatinib Radical Cystectomy Transitional Cell Carcinoma Bladder</brief_title>
	<detailed_description>OUTLINE : This multi-center study . This pilot study design determine safety feasibility treatment dasatinib 100 mg administer orally daily 4 week duration prior radical cystectomy patient muscle-invasive transitional cell carcinoma bladder ineligible and/or willing forgo neoadjuvant cisplatin-based combination chemotherapy . If surgery delay imperative , dasatinib therapy continue least 24 hour plan surgery . ECOG Performance Status 0-1 Life Expectancy : Not specify Hematopoietic : - Absolute Neutrophil Count ( ANC ) &gt; 1.5 K/mm3 - Platelets &gt; 100 K/mm3 - INR &lt; 1.2 Hepatic : - Total bilirubin &lt; 2.0 X Upper Limit Normal ( ULN ) - Aspartate aminotransferase ( AST ) ≤ 2.5 X ULN . - Alanine aminotransferase ( ALT ) ≤ 2.5 X ULN Renal : - Serum creatinine &lt; 2 X ULN Cardiovascular : - No uncontrolled angina , congestive heart failure MI within 6 month prior registration study . - No diagnosed congenital long QT syndrome ( congenital disorder characterize prolongation QT interval ECG propensity ventricular tachyarrhythmias , may lead syncope , cardiac arrest , sudden death ) . - No history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de Pointes ) . - No prolonged QTc interval pre-entry electrocardiogram ( &gt; 450 msec ) , obtain within 28 day prior register study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Histological proof muscleinvasive transitional cell carcinoma bladder ( stage IIIVa ) evidence metastatic disease ( focal squamous and/or adenocarcinoma differentiation define ≤ 10 % tumor volume allow , sarcomatoid smallcell component allow ) . Patient degree fixation pelvic sidewall eligible . Patients must willing undergo Cystoscopy , prior registration study tumor block available . Eligible radical cystectomy per attend urologist . All patient must willing forego neoadjuvant cisplatinbased combination chemotherapy understand option postsurgery must deem ineligible cisplatinbased combination chemotherapy attend medical oncologist . Prior radiation therapy allow provide radiation therapy administer urinary bladder . Written inform consent HIPAA authorization release personal health information . Age &gt; 18 year time consent . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 4 week treatment discontinuation . Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . Females must breastfeed . Ability take oral medication ( dasatinib must swallow whole ) . No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , Gleason &lt; grade 7 prostate cancer , cancer patient diseasefree least 5 year . No treatment investigational agent within 30 day prior register protocol therapy . No prior systemic chemotherapy transitional cell carcinoma bladder ( prior intravesical therapy allow ) . Any prior chemotherapy must complete &gt; 5 year prior initiation therapy . Following concomitant medication must discontinue 7 day prior registration study duration dasatinib therapy : Bisphosphonates due risk hypocalcemia ; Drugs generally accept risk cause Torsades de Pointes ; prohibit CYP3A4 inhibitors/inducers/substrates ; Anticoagulation and/or antiplatelet therapy avoid potential bleeding risk . No clinically significant infection judge treat investigator . No pleural pericardial effusion grade . history diagnose congenital bleeding disorder ( e.g. , von Willebrand 's disease ) No history diagnose acquire bleed disorder ( e.g. , acquire antifactor VIII antibody ) within one year prior registration protocol therapy . No history ongoing recent ( within &lt; 3 month prior registration protocol therapy ) significant gastrointestinal bleeding . No known history hypokalemia correct prior registration protocol therapy . No known history hypomagnesemia correct prior registration protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>